TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 7719358
Drug: Moxisylyte hydrochloride
Normalized name: Moxisylyte hydrochloride
DrugBank: Moxisylyte (DB09205)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moxisylyte hydrochloride (0.5 mg/kg)
Study: 2332986
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of chlorambucil and prednisolone
Study: 204058
Drug: Gaviscon tablets
Normalized name: Gaviscon
DrugBank: Alginic acid (DB13518)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gaviscon tablets
Study: 28587616
Drug: Mirococept 10
Normalized name: Mirococept
DrugBank: Mirococept (DB06492)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mirococept 10 mg
Study: 28587616
Drug: Mirococept (5-25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mirococept (5-25 mg, dose allocation based on interim analysis)
Study: 22652183
Drug: Pixantrone dimaleate
Normalized name: Pixantrone dimaleate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pixantrone dimaleate (85 mg/m² intravenously on days 1, 8, and 15 of a 28-day cycle, for up to six cycles)
Study: 22652183
Drug: Comparator (vinorelbine,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparator (vinorelbine, oxaliplatin, ifosfamide, etoposide, mitoxantrone, or gemcitabine at prespecified standard doses and schedules)
Study: 18563435
Drug: DHA (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: DHA (2 g/day) + EPA (3 g/day)
Study: 15804658
Drug: Ototopical treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ototopical treatments for chronic suppurative otitis media; details on dosage and duration not available.
Study: 11872916
Drug: Statin agents
Approvals — FDA: no, EMA: no, PMDA: no
Description: Statin agents
Study: 11872916
Drug: Traditional antithrombotic
Normalized name: antithrombin III
DrugBank: Antithrombin III human (DB11598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Traditional antithrombotic agents
Study: 10353432
Drug: Desipramine 100
Normalized name: desipramine 100 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Desipramine 100 mg
Study: 1384397
Drug: Hydromorphone alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydromorphone alone by bolus administration
Study: 1384397
Drug: Hydromorphone with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydromorphone with a continuous (basal) infusion
Study: 1384397
Drug: Hydromorphone in
Normalized name: hydromorphone Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydromorphone in combination with 0.08% bupivacaine by bolus administration
Study: 1384397
Drug: Hydromorphone and
Normalized name: hydromorphone and naloxone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydromorphone and bupivacaine, with a concurrent infusion of both drugs
Study: 3893680
Drug: MDF +
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: MDF + Misonidazole (1.25 g/m2 three times weekly for the first 3 weeks)
Study: 30032883
Drug: Transport on
Normalized name: Gel-One
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transport on a gurney without premedication (Group G)
Study: 30032883
Drug: Transport on
Normalized name: Gel-One
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transport on a gurney with oral midazolam 0.5 mg kg-1 (Group M)
Study: 19526249
Drug: Praneem tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Praneem tablet
Study: 15451335
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of oral misoprostol (600 microg)
Study: 15451335
Drug: Repeated dose
Normalized name: eicosyl povidone (2 eicosyl branches-repeat)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Repeated dose of oral misoprostol (1200 microg total, given as 600 microg every 4 hours)
Study: 15451335
Drug: Repeated dose
Normalized name: eicosyl povidone (2 eicosyl branches-repeat)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Repeated dose of oral misoprostol (1200 microg total)
Study: 11352373
Drug: Cognitive behavioural
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive behavioural therapy (CBT) - 2 hour session
Study: 9671370
Drug: 5 ng/kg/min
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 ng/kg/min PGE1 and 6 IU/kg/hr heparin
Study: 9671370
Drug: 20 ng/kg/min
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 ng/kg/min PGE1 and 6 IU/kg/hr heparin
Study: 7743685
Drug: Enoximone (bolus-infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enoximone (bolus-infusion of 0.5 mg/kg over 10 min followed by an infusion of 5 micrograms/kg/min up to 20 micrograms/kg/min)
Study: 7743685
Drug: Epinephrine/nitroglycerin (infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epinephrine/nitroglycerin (infusion of 0.05 and 0.5 micrograms/kg/min, respectively, for 4 hours postoperatively)
Study: 2201732
Drug: Zopiclone 7.5
Normalized name: zopiclone 7.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zopiclone 7.5 mg at bed time
Study: 7282598
Drug: High plasma
Approvals — FDA: no, EMA: no, PMDA: no
Description: High plasma vitamin C levels (16.28 +/- 3.75 mg/l) due to supplementation
Study: 7282598
Drug: Low plasma
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low plasma vitamin C levels (6.15 +/- 3.88 mg/l)
Study: 31796486
Drug: Home treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Home treatment (n=101)
Study: 31796486
Drug: Hospital treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hospital treatment (n=102)
Study: 28100019
Drug: HVPG-guided therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: HVPG-guided therapy
Study: 26520144
Drug: AC (adriamycin
Approvals — FDA: no, EMA: no, PMDA: no
Description: AC (adriamycin 60 mg/m(2), cyclophosphamide 600 mg/m(2)) followed by docetaxel 100 mg/m(2) with primary GCSF prophylaxis
Study: 26520144
Drug: FEC (5‐fluorouracil
Approvals — FDA: no, EMA: no, PMDA: no
Description: FEC (5‐fluorouracil 500 mg/m(2), epirubicin 100 mg/m(2), cyclophosphamide 500 mg/m(2)) followed by docetaxel 75 mg/m(2)
Study: 23640486
Drug: Hypolipidemic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypolipidemic therapy (fenofibrate, niacin, diet, and exercise)
Study: 22093195
Drug: Fixed-dose combination
Normalized name: Progestogens and estrogens, fixed combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed-dose combination (FDC) comprising aspirin (100 mg), ramipril (2.5, 5, or 10 mg), and simvastatin (40 mg)
Study: 22093195
Drug: Separate administration
Normalized name: Atractylis separate root
DrugBank: Atractylodes lancea root (DB14693)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Separate administration of aspirin, ramipril, and simvastatin
Study: 17710007
Drug: Khan Kinetic
Normalized name: Kineticream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Khan Kinetic Treatment (KKT)
Study: 16163169
Drug: Increasing the
Normalized name: THE-630
DrugBank: THE-630 (DB16750)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Increasing the dose of radiotherapy or adding a brachytherapy boost
Study: 11528196
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg vardenafil
Study: 11528196
Drug: Both doses
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both doses of vardenafil (20 mg and 40 mg)
Study: 9749589
Drug: Deprenyl (selegiline)
Normalized name: L-deprenyl-D2 C-11
DrugBank: L-deprenyl-D2 C-11 (DB12650)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Deprenyl (selegiline) 10 mg/day
Study: 9749589
Drug: Open-label deprenyl
Normalized name: strontium chloride, 89Sr-labeled
DrugBank: Strontium chloride Sr-89 (DB09498)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Open-label deprenyl treatment
Study: 7810015
Drug: Budesonide (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Budesonide (400 microgrammes daily via Turbuhaler)
Study: 6102896
Drug: Slow-release preparations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Slow-release preparations of Metoprolol
Study: 6102896
Drug: Slow-release preparations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Slow-release preparations of Propranolol
Study: 30760320
Drug: Umbilical therapy
Normalized name: Bos taurus umbilical cord preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Umbilical therapy with Lishui Xiaogu cataplasm plus red light irradiation along with conventional treatment
Study: 30760320
Drug: Placebo cataplasm
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo cataplasm plus red light irradiation along with conventional treatment
Study: 23663658
Drug: Bosentan (endothelin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bosentan (endothelin receptor antagonist) administered for 14 weeks
Study: 21832027
Drug: Vitamin D-fortified
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D-fortified milk (mean intake of 3.7 μg/d)
Study: 15223899
Drug: FTY720 0.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: FTY720 0.25 mg
Study: 15223899
Drug: FTY720 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: FTY720 0.5 mg
Study: 15223899
Drug: FTY720 1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: FTY720 1.0 mg
Study: 17061999
Drug: FTY720 2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: FTY720 2.5 mg
Study: 9569474
Drug: Two doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two doses of recombinant hepatitis B vaccine (10 micrograms or 20 micrograms of HBsAg per dose), administered 6 months apart
Study: 9569474
Drug: Booster dose
Normalized name: SARS-COV-2 (COVID-19) Vaccine, mRNA (Moderna) 50 MCG/0.5 ML Intramuscular Suspension [MODERNA COVID-19 VACCINE BOOSTER DOSE]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Booster dose of vaccine given 2 years later
Study: 31428894
Drug: Rikkunshito (RKT)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rikkunshito (RKT) 7.5 g/day for 14 days
Study: 28615257
Drug: Iron supplement
Normalized name: Iron supplement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iron supplement (18 mg/d)
Study: 23715625
Drug: Pazopanib 800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pazopanib 800 mg
Study: 20966119
Drug: New equations
Approvals — FDA: no, EMA: no, PMDA: no
Description: New equations to estimate creatinine excretion rate (CER) with serum phosphorus
Study: 20966119
Drug: New equations
Approvals — FDA: no, EMA: no, PMDA: no
Description: New equations to estimate creatinine excretion rate (CER) without serum phosphorus
Study: 20966119
Drug: Existing equations
Normalized name: miconazole
DrugBank: Miconazole (DB01110)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Existing equations to estimate creatinine excretion rate (CER)
Study: 14551493
Drug: S/B vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: S/B vaccine groups
Study: 8752186
Drug: Lovastatin 20
Normalized name: lovastatin 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lovastatin 20 mg twice daily
Study: 8752186
Drug: Lovastatin 40
Normalized name: lovastatin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lovastatin 40 mg twice daily
Study: 1418102
Drug: Lovastatin 80
Normalized name: fluvastatin 80 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lovastatin 80 mg twice daily
Study: 1418102
Drug: Simvastatin 20
Normalized name: simvastatin 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simvastatin 20 mg twice daily
Study: 1418102
Drug: Simvastatin 40
Normalized name: simvastatin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simvastatin 40 mg twice daily
Study: 1418102
Drug: Simvastatin 80
Normalized name: simvastatin 80 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simvastatin 80 mg twice daily
Study: 29242283
Drug: BEZ235 400
Approvals — FDA: no, EMA: no, PMDA: no
Description: BEZ235 400 mg twice daily
Study: 27074806
Drug: 12-week multidisciplinary
Normalized name: risedronate
DrugBank: Risedronic acid (DB00884)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 12-week multidisciplinary team care programme including a hand function treatment module
Study: 25022113
Drug: Jin's three-needle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Jin's three-needle therapy (acupuncture)
Study: 25022113
Drug: Desloratadine oral
Normalized name: desloratadine Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Desloratadine oral suspension (5 mg once a day for 20 days)
Study: 22545252
Drug: Topical nystatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical nystatin 4 times/day for 14 days
Study: 11876709
Drug: H. pylori
Normalized name: H. PYLORI AGENTS
Approvals — FDA: no, EMA: no, PMDA: no
Description: H. pylori eradication treatment (1-week omeprazole-based triple therapy, followed by 7-week omeprazole)
Study: 2184527
Drug: Combination tablet
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination tablet (RHZ), 5 tablets per day on weekdays for 100 treatment-days
Study: 2184527
Drug: Four-drug regimen
Normalized name: Four-Way
Approvals — FDA: no, EMA: no, PMDA: no
Description: Four-drug regimen (RHZS) (streptomycin, rifampicin, isoniazid and pyrazinamide)
Study: 376950
Drug: Treatment 1:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment 1: Actinomycin-D (Act-D), 0.01 mg/kg IV, days 1-5; L-PAM, 4 mg PO, days 1-10 every six weeks
Study: 376950
Drug: Treatment 2:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment 2: Act-D, 0.01 mg/kg IV, days 1-5; L-PAM, 4 mg PO, days 1-10; Vincristine, 1 mg IV, days 1, 8, 15, 22, 29, 36, repeat every six weeks
Study: 376950
Drug: Treatment 3:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment 3: Act-D, 0.01 mg/kg IV, days 1-5; L-PAM, 4 mg PO, days 1-10; NSC-1026, 200 mg/kg IV, days 1-6
Study: 376950
Drug: Treatment 4:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment 4: Adriamycin, 0.4 mg/kg IV, days 1, 2, 3, 8, 9, 10, then 2XWK starting day 15 (max. 1,200 mg)
Study: 28366181
Drug: ALA +
Normalized name: Alpha-Lipoic Acid
DrugBank: Lipoic acid (DB00166)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ALA + quercetin (190 mg/d)
Study: 28366181
Drug: ALA +
Normalized name: Alpha-Lipoic Acid
DrugBank: Lipoic acid (DB00166)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ALA + placebo (3.3 g/d ALA)
Study: 21760724
Drug: Moxifloxacin (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moxifloxacin (400 mg PO once daily for 5 days)
Study: 21760724
Drug: Amoxicillin/clavulanic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxicillin/clavulanic acid (875/125 mg PO twice daily for 7 days)
Study: 19843742
Drug: 64-MDCT with
Approvals — FDA: no, EMA: no, PMDA: no
Description: 64-MDCT with oral and IV contrast media (Group 1)
Study: 17426111
Drug: Triiodothyronine (T(3))
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triiodothyronine (T(3)) infusion for 24 hours after surgery
Study: 17426111
Drug: Placebo infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo infusion for 24 hours after surgery
Study: 15553821
Drug: Shengxuening (SXN)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Shengxuening (SXN) 0.1 g, three times per day for 30 days
Study: 15553821
Drug: Ferrous gluconate
Normalized name: Ferrous Gluconate
DrugBank: Ferrous gluconate (DB14488)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ferrous gluconate 0.1 g, three times per day for 30 days
Study: 7972781
Drug: Low-dose acetylsalicylic
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose acetylsalicylic acid (25 mg) and dipyridamole (200 mg) (ASAD) twice daily for 1 year
Study: 7972781
Drug: Low-dose acetylsalicylic
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose acetylsalicylic acid (25 mg) and dipyridamole (200 mg) (ASAD)
Study: 2685207
Drug: Nortriptyline (specific
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nortriptyline (specific dosage and duration not mentioned)
Study: 2685207
Drug: Patients receiving
Normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients receiving antidepressants at the time of assessment (specific treatment not mentioned)
Study: 2685207
Drug: Antidepressant treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antidepressant treatment initiated after assessment (specific treatment not mentioned)
Study: 22269198
Drug: Single session
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single session filling without calcium hydroxide medication
Study: 22269198
Drug: Calcium hydroxide-based
Normalized name: Calcium Hydroxide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium hydroxide-based intracanal medication Calen®
Study: 12631443
Drug: Oral antioxidative
Normalized name: antioxidant 119
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral antioxidative treatment (Quatral) once daily for 16 weeks
Study: 10698386
Drug: Adenosine (12
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adenosine (12 mg intravenously)
Study: 9329380
Drug: Estrogen (hormone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Estrogen (hormone replacement therapy)
Study: 7870919
Drug: Alcohol (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alcohol (0.5 g/l)
Study: 7870919
Drug: Alcohol +
Normalized name: Benzyl alcohol + eucalyptus oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alcohol + Diazepam (5 mg)
Study: 23356032
Drug: Treatment lasting
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment lasting six months (intervention group)
Study: 10393392
Drug: Oral isosorbide-5-mononitrate
Normalized name: Isosorbide 5-mononitrate
DrugBank: Isosorbide mononitrate (DB01020)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral isosorbide-5-mononitrate (ISMN) 50 mg once daily
Study: 8697554
Drug: Intrathecal morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrathecal morphine alone (phase M)
Study: 8697554
Drug: Co-administration of
Approvals — FDA: no, EMA: no, PMDA: no
Description: Co-administration of ketamine (1.0 mg) with morphine (phase M + K)
Study: 1992660
Drug: DFO 40
Normalized name: DFO
DrugBank: Deferoxamine (DB00746)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: DFO 40 mg/kg
Study: 1992660
Drug: DFO 80
Normalized name: DFO
DrugBank: Deferoxamine (DB00746)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: DFO 80 mg/kg
Study: 1992660
Drug: DFO (both
Approvals — FDA: no, EMA: no, PMDA: no
Description: DFO (both doses)
Study: 1992660
Drug: DFO (higher
Approvals — FDA: no, EMA: no, PMDA: no
Description: DFO (higher doses)
Study: 26769016
Drug: 4 mL
Normalized name: ethanol 1.4 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mL 7% hypertonic saline
Study: 17122083
Drug: Rosi (8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rosi (8 mg/d)
Study: 17122083
Drug: Rosi (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rosi (20 mg/kg·d)
Study: 17122083
Drug: Rosi treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rosi treatment (1 μM)
Study: 12856053
Drug: Four weeks
Normalized name: Four-Way
Approvals — FDA: no, EMA: no, PMDA: no
Description: Four weeks of aminosidine (paromomycin) ointment
Study: 12856053
Drug: Two weeks
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two weeks of aminosidine (paromomycin) ointment and two weeks of placebo
Study: 18807128
Drug: omeprazole 10
Normalized name: omeprazole 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: omeprazole 10 mg
Study: 1742515
Drug: ranitidine 150
Normalized name: ranitidine 150 MG
DrugBank: Ranitidine (DB00863)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ranitidine 150 mg
Study: 1745027
Drug: Drug therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug therapy only (control group)
Study: 29094048
Drug: Single-dose Praziquantel
Normalized name: Praziquantel
DrugBank: Praziquantel (DB01058)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Single-dose Praziquantel (40 mg/kg)
Study: 29094048
Drug: Double-dose Praziquantel
Normalized name: Praziquantel
DrugBank: Praziquantel (DB01058)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Double-dose Praziquantel (40 mg/kg)
Study: 19229988
Drug: Standard dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard dose budesonide (9 mg/day for 7 weeks followed by 6 mg/day for 3 weeks)
Study: 19229988
Drug: Induction with
Normalized name: Marcaine with Epinephrine Injectable Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction with 12 mg/day for the first month followed by the same regimen as Group 1
Study: 17698116
Drug: Preoperative circulating
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Preoperative circulating plasminogen activator inhibitor type I
Study: 17698116
Drug: Addition of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Addition of plasminogen activator inhibitor type I to preoperative multivariate model
Study: 17698116
Drug: Addition of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Addition of plasminogen activator inhibitor type I to postoperative model
Study: 10928308
Drug: Tiapride 100-300
Normalized name: tiapride
DrugBank: Tiapride (DB13025)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tiapride 100-300 mg/day
Study: 10928308
Drug: Haloperidol 2-6
Normalized name: haloperidol 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Haloperidol 2-6 mg/day
Study: 8677757
Drug: Effective chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Effective chemotherapy in ANLL responders
Study: 8677757
Drug: Granulocyte-macrophage colony-stimulating
Normalized name: Granulocyte macrophage-colony stimulating factor
DrugBank: Molgramostim (DB12525)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Granulocyte-macrophage colony-stimulating factor (GM-CSF) therapy in ANLL responders
Study: 29602597
Drug: Atypical antipsychotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atypical antipsychotic drugs (monotherapy for 6 weeks)
Study: 25565583
Drug: Pregabalin (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pregabalin (150 to 300 mg/d)
Study: 25332243
Drug: High-dose interferon
Normalized name: interferon-beta
DrugBank: Human interferon beta (DB14999)
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose interferon (HDI) for 1 year
Study: 15968712
Drug: Flutin capsules
Normalized name: azelastine
DrugBank: Azelastine (DB00972)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Flutin capsules (Julphar, UAE)
Study: 15968712
Drug: Prozac capsules
Normalized name: fluoxetine Oral Capsule [Prozac]
DrugBank: Fluoxetine (DB00472)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prozac capsules (Eli Lilly, UK)
Study: 12110467
Drug: Low doses
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low doses of oral amphetamine
Study: 8822427
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg of prednisolone daily for 2 weeks prior to IVF treatment
Study: 8822427
Drug: Placebo daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo daily for 2 weeks prior to IVF treatment
Study: 12542874
Drug: Subarachnoid spinal
Normalized name: bupivacaine
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subarachnoid spinal analgesia with morphine sulfate (Group A)
Study: 373871
Drug: ampicillin (12
Approvals — FDA: no, EMA: no, PMDA: no
Description: ampicillin (12 g/d)